APOE4, Brain Blood Vessels, and Cellular Cleanup: What New Research Reveals

By Daniel Soule
Owner & Clinic Director, HormoneSynergy® Clinic
Portland & Lake Oswego, Oregon

An APOE4 result often arrives with more anxiety than explanation. A person learns that their risk of Alzheimer’s disease is higher, then has to decide what that information means for the rest of their life. Research becomes useful when it begins to explain the biology behind the association and gives us better questions to ask.

Two papers from researchers at Mount Sinai examine how APOE4 affects cells involved in maintaining the brain’s circulation and processing proteins. They are separate studies, with different mechanisms and experimental interventions. Reading them together offers a more detailed view of how genetic risk may alter the environment in which neurons live.^{1, 2}

When vessel-supporting cells change their role

Pericytes help maintain the small vessels that supply brain tissue. In the Cell study, researchers found reduced pericyte abundance in APOE4 human brains, alongside cells with features of myofibroblasts, which produce scar-associated material. Experiments supported a transition from pericytes into this altered cell state.¹

Elevated signaling through transforming growth factor beta, or TGF-β, drove the transition. The transformed cells secreted fibronectin, a structural protein that promoted amyloid accumulation around blood vessels. The findings connect APOE4 with a specific sequence of cellular changes that can contribute to vascular fibrosis and amyloid deposition.¹

Cholesterol and cellular cleanup

The second study, published in Cell Stem Cell, used stem-cell-derived, three-dimensional brain tissue called miBrains. In models carrying two APOE4 copies, cholesterol accumulated in astrocytes and impaired their endolysosomal machinery, which processes and breaks down material inside cells. Alpha-synuclein was degraded less effectively, allowing pathological forms to develop and seed inclusions in neurons.²

Alpha-synuclein is especially relevant to Parkinson’s disease and Lewy body dementia. This paper therefore contributes to a wider understanding of neurodegeneration; its results should not be presented as though it studied only Alzheimer’s amyloid.²

The distinction between cellular cleanup and glymphatic clearance also matters. This experiment examined protein processing inside astrocytes. It did not demonstrate that a treatment restored the brain’s fluid-based glymphatic clearance. Calling both “waste removal” can make separate biological processes sound interchangeable.²

What the word “reversible” means here

In the vascular study, inhibiting TGF-β signaling reversed the pericyte transition and reduced fibrosis and vascular amyloid in experimental models. In the astrocyte study, cholesterol-modifying interventions improved aspects of lysosomal function and protein handling. These are valuable demonstrations that the abnormalities can respond to intervention under the conditions studied.^{1, 2}

Patients understandably hear “reversible” as a statement about their own prognosis. Neither study tested reversal of Alzheimer’s disease in patients, and neither tested ReCODE. Evidence that an experimental intervention changes a cellular pathway cannot establish that a clinical program produces the same effect.

Some descriptions place these findings within a “connection versus protection” model, in which stressed cells adopt defensive behaviors at the expense of normal function. That can be a useful interpretive framework. These papers did not test a single master switch underlying Alzheimer’s disease, however, and the specific mechanisms deserve to remain visible within the broader explanation.

The relevance to preventive longevity medicine

At HormoneSynergy®, our interest in this research comes from the relationship between brain health and the rest of a person’s physiology. Our approach to cognitive longevity considers vascular and metabolic health alongside sleep, physical activity, nutrition, medications, and other factors that can affect cognitive function. The clinical question is which concerns are present in the person sitting in front of us and which can be meaningfully addressed.

There is clinical evidence for addressing multiple risk factors together, separate from these laboratory findings. In the two-year US POINTER randomized trial, a structured program incorporating exercise, dietary improvement, cognitive and social activity, and cardiovascular monitoring produced a modestly greater improvement in global cognitive performance than a self-guided program. The study supports organized, sustained attention to several aspects of health. It did not show that the program reversed the APOE4 mechanisms described here or establish prevention of dementia.³

The 2024 Lancet Commission likewise places blood pressure, diabetes, smoking, physical inactivity, hearing and vision loss, social isolation, and high LDL cholesterol within a broader prevention framework. These are population-level findings that help guide care; they cannot guarantee an individual outcome.⁴

For someone concerned about inherited risk, this provides a reasonable starting point for a medical conversation. Blood pressure and atherogenic lipoproteins belong in that discussion, as do glucose regulation, exercise capacity, sleep symptoms, hearing, and day-to-day function. Our preventive cardiology work and discussion of restorative sleep explain how these concerns fit into preventive longevity medicine.

We have also written about ReCODE and the principles we have incorporated into cognitive longevity care. The new papers add to the mechanistic research surrounding APOE4. They do not validate every component of a protocol or establish that improvements in routine clinical markers correspond to repair of pericytes or astrocytes.

We can take the findings seriously while allowing the clinical evidence to develop. More precise explanations of APOE4 may eventually help physicians choose treatments that address particular vulnerabilities. For now, our responsibility is to explain what is known, address the risks we can assess, and follow patients over time with realistic expectations.

References

1. Schuldt BR, Haworth-Staines D, Perez-Arevalo A, et al. A pericyte-to-myofibroblast transition links APOE4 to cerebrovascular degeneration. Cell. Published online September 24, 2026. doi:10.1016/j.cell.2026.08.058.
2. Mesentier-Louro LA, Goldman C, Gaese S, et al. Cholesterol dysregulation in APOE4 astrocytes promotes α-synuclein pathology in miBrains. Cell Stem Cell. 2026;33(9):1459–1476.e10. doi:10.1016/j.stem.2026.08.001.
3. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial. JAMA. 2025;334(8):681–691. doi:10.1001/jama.2025.12923.
4. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572–628. doi:10.1016/S0140-6736(24)01296-0.

Educational information; individual evaluation is required for diagnosis and treatment. HormoneSynergy® provides preventive longevity care alongside an established primary care relationship.